

Reetan Patel

From: Chris Hiley [REDACTED]
Sent: 04 November 2005 16:51
To: Alana Miller
Subject: Docetaxel consultation


Thank you for sending the Assessment Report to us.

We welcome the clear acknowledgement that Docetaxel plus prednisolone is the most effective treatment for men with mHRPC. We are concerned however that the NHS is provided with a financial 'let out' based on the cost per QALY. This raises concerns about the nature of the final appraisal and response of men with mHRPC to it. As the drug is the only one that extends life for these men, and has quality of life benefits as well, there will be considerable public and patient concern that it may be sidelined for economic reasons. The economic model needs to be interrogated fully to make sure that its assumptions really are defensible. As high cost drugs may be becoming the norm there has to be some organised thinking about how to manage those demands in the future.

Chris Hiley
Head of Policy and Research
The Prostate Cancer Charity
3 Angel Walk
Hammersmith
LONDON
W6 9HX

Main: 020 8222 7622
[REDACTED]

Helpline: 0845 300 8383
Helpline textphone: 0845 300 8484
Web: www.prostate-cancer.org.uk
[REDACTED]



The National Prostate Cancer Conference
Thursday 3rd November, Congress Centre, London
[REDACTED]

Delivered via MessageLabs

08/12/2005